FIT Biotech Oy
Company announcement
March 17, 2017 at 12:10 EET
FIT Biotech’s Annual Report 2016 published
FIT Biotech Oy’s Annual Report for the year 2016 has been published today. The Annual Report contains the financial statements and the review of the Board of Directors.
The Annual Report is available in PDF format in Finnish and English as an appendix to this release and on the company’s web site at www.fitbiotech.com in section Investors/Financial reports/Annual reports.
FIT Biotech Oy
For further information:
Chairman of the Board of Directors Juha Vapaavuori
E-mail: juha.vapaavuori@fitbiotech.com
Tel: +358 50 372 0824
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
